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In the last few years, many studies have confirmed that growth
factors not only promote tissue proliferation but also induce
malignant transformation (Cross and Dexter, 1991). Over-
expression of growth factors has been found in many human
tumours, and this phenomenon is often considered to be a cause
of carcinogenesis (Aaronson, 1991). MK is a product of a retinoic
acid-responsive gene and belongs to the new family of heparin-
binding growth/differentiation factors (Kadomatsu et al, 1988,
1990; Tomomura et al, 1990a,  b; Muramatsu, 1993, 1994). It
plays a role in neuronal survival and differentiation (Michikawa
et al, 1993; Muramatsu et al, 1993; Unoki et al, 1994) and is also
expressed at higher levels in human tumours, such as Wilms’
tumours (Tsutsui et al, 1993), lung carcinomas (Garver et al,
1993), breast carcinomas (Garver et al, 1994), neuroblastomas
(Nakagawara et al, 1995), hepatocellular, gastric, pancreatic and
colon carcinomas (Aridome et al, 1995) and urinary bladder
carcinomas (O’Brien et al, 1996), than in corresponding normal
tissues. However, it remains unknown whether MK plays a role 
in either an early stage of carcinogenesis or a later stage. The
progression from colorectal neoplasia to an invasive cancer
provides an excellent opportunity for studying the status of MK,
because most colorectal carcinomas appear to arise from
adenomas. In the present study, we attempted to clarify the role of
MK in carcinogenesis through examination of its expression in
adenomas with different grades of dysplasia and in carcinomas at
various stages by means of Northern blotting, Western blotting
and immunostaining.
MATERIALS AND METHODS
Sample collection
Fifty-six adenoma specimens were obtained from 46 patients (16
with mild-, 34 with moderate- and six with severe-grade
dysplasia) who had undergone polypectomy at the Nogaki
Hospital of Disease of the Anus and Rectum in Nagoya, Japan,
from January 1997 to February 1998. Two or more specimens per
case were available from nine patients, i.e. two adenomas with
mild- and moderate-grade dysplasia in six patients, two adenomas
with moderate-grade dysplasia in two patients and three adenomas
with two moderate- and one severe-grade dysplasia in one patient.
Paired specimens of carcinomas and corresponding normal tissues
over 4 cm from the carcinoma lesions were collected from 32
patients (six stage A, 14 stage B and 12 stage C) who had not
received any form of chemotherapy and radiation and who had
undergone colorectal surgery at the Department of Surgery II,
Nagoya University School of Medicine, between September 1996
and June 1997. There was no overlap between the above-
mentioned adenoma patients and carcinoma patients. In addition,
colorectal carcinoma, adenoma and normal tissue specimens in the
same individual were obtained from three patients. The adenomas
were graded according to the degree of dysplasia by means of
histopathology, and the colorectal carcinomas were staged
according to the Astler–Coller modification of Dukes’ classifica-
tion (Aster and Coller, 1954).
The tissues were obtained during surgery. Each specimen, if of
sufficient volume, was divided into two parts, except for routine
pathological examination with haematoxylin and eosin. One part
was quickly frozen in liquid nitrogen and stored at –80°C until
RNA extraction using guanidium thiocyanate, followed by ultra-
centrifugation in a caesium chloride solution and/or until protein
extraction and heparin–Sepharose column chromatography. 
The other part was fixed using 4% paraformaldehyde in 0.1 M
Expression of midkine in the early stage of
carcinogenesis in human colorectal cancer
C Ye1, M Qi2, Q-W Fan2, K Ito3, S Akiyama3, Y Kasai3, M Matsuyama1, T Muramatsu2 and K Kadomatsu2
1Department of Pathology, Fujita Health University School of Medicine, Toyoake, Aichi 470-1192, Japan; 2Department of Biochemistry and 3Department of
Surgery II, Nagoya University School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan
Summary It has been suggested that a heparin-binding growth factor, midkine (MK), plays an important role in carcinogenesis because of 
its frequent overexpression in various malignant tumours. To clarify whether or not MK contributes to the early stage of carcinogenesis,
we examined the status of MK mRNA in 20 adenomas with moderate- and severe-grade dysplasia, 28 carcinomas and 28 corresponding
normal tissues, by means of Northern blotting. The MK expression level was significantly more elevated in adenomas than in normal tissues
(P < 0.001, unpaired Student’s t-test). A difference was also observed between carcinomas and the corresponding normal tissues (P < 0.04,
paired Student’s t-test). Moreover, MK immunostaining was positive in the adenomas with moderate- and severe-grade dysplasia and in the
carcinomas, but not in mild-grade dysplasia or in normal tissues. These findings were in line with those on Western blotting. In three patients
with both adenomas with moderate- or severe-grade dysplasia and carcinomas, elevated MK expression was observed in the neoplastic
lesions. This is the first report of the association of elevated MK expression with the early stage of carcinogenesis in humans.
Keywords: carcinogenesis; colorectal adenoma; colorectal carcinoma; midkine; pleiotrophin
179
British Journal of Cancer (1999) 79(1), 179–184
© 1999 Cancer Research Campaign
Received 9 September 1997
Revised 1 April 1998
Accepted 14 May 1998
Correspondence to: K KadomatsuDulbecco’s phosphate-buffered saline (PBS) (pH 7.2) for about 
16 h at 4°C. Paraffin blocks were then made for sectioning for 
MK immunostaining.
Because of the limited number of specimens, the numbers used
for analyses were as follows: adenomas, 20 for Northern blot
analysis, 50 for immunostaining and five for Western blot analysis
(in other words, three for Northern, Western and immunostaining,
two for Northern and Western, 11 for Northern and immuno-
staining, four for Northern and 36 for immunostaining); paired
carcinoma and corresponding normal tissue specimens, 28 pairs
for Northern blot analysis, 22 pairs for immunostaining and 14 for
Western blot analysis (eight pairs for Northern, Western and
immunostaining, four pairs for Northern and Western, 11 pairs for
Northern and immunostaining, one pair for Western and immuno-
staining, five pairs for Northern, two pairs for immunostaining and
one pair for Western); and carcinoma, adenoma and normal tissue
samples from the same individuals, two for Northern blot analysis
and immunostaining, and one for Northern and Western blot
analyses as well as immunostaining.
Northern and Western blot analysis
Northern blot analysis was performed as described previously
(Kadomatsu et al, 1993). A 487-bp human MK cDNA fragment
(nucleotide numbers 76–562) (Tsutsui et al, 1993) or a 3-kbp
human  b-actin cDNA (Nakajima-Iijima et al, 1993) was used as a
probe. After appropriate exposure of the autoradiograms, the signal
intensity was determined with computer software, NIH image.
For protein extraction, tissues, 100 mg each, were homogenized
in ten volumes of ice-cold lysis buffer (10 mM Tris HCl, pH 7.6,
1% Triton X-100, 0.2 M sodium chloride), and then centrifuged at
10 000 g for 20 min at 4°C. One hundred microlitres of 10%
heparin–Sepharose was added to the supernatant, followed by
rotation overnight at 4°C. After washing three times with the lysis
buffer and three times with the washing buffer (10 mM Tris HCl,
pH 7.6, 0.2% Triton X-100, 0.5 M sodium chloride), protein
samples (each corresponding to 40 mg of tissue) were subjected to
SDS-polyacrylamide gel electophoresis as described by Laemmli
(1970), and then transferred to a nitrocellullose membrane. The
MK protein was detected with rabbit anti-human MK antibodies
(dilution, 1:3000) (provided by Drs S. Ikematsu and S. Sakuma,
Meiji Cell Technology Center) and horseradish peroxidase-
labelled anti-rabbit IgG (Jackson Laboratory; dilution, 1:5000),
with the use of an ECL system (Amersham).
Immunohistochemistry
Paraffin sections (4 mm) were sequentially incubated at room
temperature as follows: (1) with 10% skim milk to remove
possible background for 20 min; (2) with affinity-purified rabbit
anti-mouse MK antibodies at its working dilution (1:200) for 1 h;
(3) with 0.3% hydrogen peroxide in methanol for 30 min to block
endogenous peroxidase activity; (4) with the secondary antibodies
(biotinylated anti-rabbit IgG; Southern Biotechnology Associates,
Birmingham, AL, USA) for 30 min; (5) with avidin–horseradish
peroxidase (Vector, Burlingame, CA, USA) for 30 min; and (6)
with 3,3-diaminobenzidine containing hydrogen peroxide for 
5 min for development. Washing was performed three times with
PBS buffer (pH 7.4) after each incubation. The nuclei were stained
with 1% methyl green (pH 4.0). The primary antibodies were
replaced with PBS buffer as a negative control.
RESULTS
Twenty adenomas (16 with mild- and four with severe-grade
dysplasia) and 28 pairs of carcinomas and corresponding normal
tissues were examined for MK RNA expression by means of
Northern blotting. Representatives are shown in Figure 1A. On
comparison of the densities of the autoradiograms with b-actin, the
mean ratio of MK mRNA was found to be 1.35 (SD = 0.9) for
normal colorectal tissues, but 3.72 (SD = 2.4) for adenomas. Since
normal tissue corresponding to an adenoma was very difficult to
obtain on polypectomy, we used the value for normal colorectal
tissues from independent individuals with carcinomas as a relative
standard. There was no statistical difference in age and gender
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Figure 1 MK RNA expression in colorectal adenomas and carcinomas. 
(A) MK mRNA overexpressed in colorectal adenomas. Cases 4 and 5 had
tubular and villous adenomas with moderate-grade dysplasia, respectively,
and case 8 had a tubular adenoma with moderate-grade dysplasia. 
(B) increased MK expression in colorectal carcinomas compared with in the
corresponding normal tissues. Case 43 had a colorectal carcinoma at stage
A, and cases 48 and 52 had colorectal carcinomas at stage C. N, normal
tissue; C, carcinomabetween the adenoma and carcinoma patients. A statistical differ-
ence was found between adenomas and normal tissues (P < 0.001)
using the unpaired Student’s t-test (Figure 2).
When investigating the status of MK mRNA in normal tissue
and carcinoma samples, we often observed higher expression of
MK in a carcinoma tissue than in the corresponding normal tissue,
as shown in Figure 1B. A higher level of MK expression was
observed in 19 of the 28 carcinoma samples (68%) than in the
corresponding normal tissues, a statistically significant difference
(P = 0.036) being revealed with the paired Student’s t-test (Figure
2). Thus, the level of MK mRNA was elevated from the adenoma
with dysplasia stage to the advanced carcinoma stage. In addition,
interestingly, the MK mRNA expression level in adenomas was
rather higher than that in carcinomas (P < 0.01, unpaired Student’s
t-test.
To determine the status of MK at the protein level during the
progress of colorectal carcinogenesis, immunostaining was
performed for 50 adenoma specimens, comprising 16 with mild-
grade dysplasia, 29 with moderate-grade dysplasia and five with
severe-grade dysplasia, and for 22 paired samples of carcinomas at
different stages and corresponding normal tissues. MK staining
was observed in adenomas with moderate- and severe-grade
dysplasia and in carcinomas, but not in the normal colorectal
mucosa or adenomas with mild-grade dysplasia (Figure 3 and
Table 1). The intracellular distribution of MK appeared to be
mainly in the cytoplasm, but also in some nuclei. Positive staining
was observed in none of the 16 adenomas with mild-grade
dysplasia, in 18 of the 29 with moderate-grade dysplasia, in all five
with severe-grade dysplasia (Table 1) and in all 22 carcinomas
(data not shown). The extent of positive staining paralleled the
severity of the dysplasia.
To confirm the results of immunostaining, Western blot analysis
was performed. The protein could be extracted from two
adenomas with severe-grade dysplasia, three with moderate-grade
dysplasia and 14 paired specimens of carcinomas and corre-
sponding normal tissues. In addition, samples from one case, in
which adenoma with moderate-grade dysplasia, carcinoma at stage
B and corresponding normal tissues were available, were also
subjected to Western blot analysis. The level of the MK protein
was much higher in carcinomas than in the corresponding normal
tissues in all 14 paired specimens (examples are shown in Figure
4). Strong expression of the MK protein was also detected in all
five adenomas (an example is shown in Figure 4). MK migrates as
an approximately 17-kDa molecule; thus, the faint signals higher
than this may be artifacts. Importantly, although only one case
with adenoma, carcinoma and corresponding normal tissue was
available for Western blot analysis, MK protein expression was
much higher in the adenoma and carcinoma than in the corre-
sponding normal tissue (Figure 4).
In three cases, normal, adenoma with moderate/severe-grade
dysplasia and carcinoma tissues were all available for Northern
blot analysis and immunohistochemistry. These cases showed that,
in the same individual, MK RNA expression was elevated from
the adenoma stage to the carcinoma stage, and MK protein expres-
sion revealed by immunohistochemistry exhibited a similar profile
(Table 2). These findings were consistent with the MK expression
profile observed in the mass studies described above.
DISCUSSION
Carcinogenesis is a multistep process requiring, first, that the
normally interdependent systems controlling proliferation and
differentiation are uncoupled, and, second, that proliferation is
stimulated in such a way as to result in extensive growth of 
the transformed cells. We recently demonstrated that MK has
oncogenic potential because it induces the transformation of
NIH3T3 cells and tumours in nude mice (Kadomatsu et al, 1997).
Consistent with this finding, MK expression was observed from
the precancerous lesion stage to the terminal carcinoma stage
during carcinogenesis in hepatic carcinomas induced by diethyl-
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Figure 2 Levels of MK mRNA in colorectal normal tissues, adenomas and
carcinomas. The MK mRNA level was determined by means of NIH Image
software with the b-actin gene as an internal control. The ratio of MK to b-
actin in each sample was calculated. Bars represent averages. For statistical
analysis, the unpaired and paired Student’s t-tests were used
Table 1 Relationship between MK expression and the histopathology of
colorectal adenomas
Histopathology Mild-grade Moderate-grade Severe-grade
dysplasia dysplasia dysplasia
Morphology
Tubular 0/16 12/21 1/1
Tubulovillous 0 6/8 3/3
Villous 0 0 1/1
Size
<1 cm 0/16 12/20 0
1–2 cm 0 6/9 4/4
>2 cm 0 0 1/1
Denominator, number of samples analysed using immunostaining,
numerator, number positivenitrosamine in rats (Kanda et al, manuscript in preparation). In the
present study, we showed the following: (1) strong expression 
of MK mRNA appeared at the stage of adenomas with
moderate/severe-grade dysplasia in human colorectal carcinogen-
esis; (2) the MK protein was also detected in the neoplastic tissues
at the same stages; and (3) the extent of MK-positive staining
increased according to the severity of dysplasia in human
colorectal adenomas. In some cases, the changes seen in the levels
of RNA expression were not very profound. Thus, we cannot
exclude the possibility that these changes reflect a lower state of
differentiation of the cells or an increased growth fraction, and
thus have little to do with malignant transformation. But we
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Figure 3 MK immunostaining in colorectal neoplastic tissues. MK staining can be observed in carcinoma nests (arrows in B), and some lesions of adenoma
with severe-grade dysplasia (arrows in D), but not in normal colorectal tissue (F). (A), (C) and (E) show haematoxylin and eosin staining corresponding to (B),
(D) and (F) respectively. Bars 50 mmusually observed clearly large differences, as shown in Figure 4,
between normal tissues and neoplastic tissues, including adenomas
with moderate-severe-grade dysplasia and carcinomas, in protein
expression on Western blot analysis. These findings suggest the
importance of MK in the early stage of carcinogenesis in humans.
This was further supported by the finding that MK expression was
elevated at the RNA level, as well as the protein level, from the
adenoma stage in the individuals for whom normal, adenomatous
and carcinomatous colorectal tissues were subjected to examina-
tion of MK expression (Table 2 and Figure 4).
On the other hand, MK is frequently expressed at a high level in
advanced human carcinomas. In the present study, we confirmed
this in human colorectal carcinomas, consistent with the previous
data reported by Aridome et al (1995). Concerning the possible
involvement of MK in late stages of carcinogenesis, Choudhuri 
et al (1997) reported the angiogenic activity of MK. In addition, a
positive relationship between the MK level and the clinical stages
of neuroblastomas and urinary bladder carcinomas has been
reported (Nakagawara et al, 1995; O’Brien et al, 1996).
To account for the importance of the growth factor in tumour
development, the autocrine hypothesis has classically been
proposed (Sporn and Todaro, 1980). Although the original concept
was too restrictive and autocrine growth factor secretion also
functions in normal growth regulation (Cross and Dextor, 1991;
Daughaday and Deuel, 1991), autocrine or paracrine circuits in
normal growth can also stimulate the growth of neighbouring
oncogene-activated cells, and then the oncogene-activated cells
may obtain a growth advantage by maintaining local critical
concentrations of some growth factors (Dawson and Wynford-
Thomas, 1995). There have been many reports on association of
the expression of growth factors and early carcinogenesis. Insulin-
like growth factor II is expressed in precancerous altered hepatic
foci in woodchuck hepatitis virus carriers (Yang et al, 1993).
Transforming growth factor a is expressed in precancerous altered
hepatic foci in a rat hepatocarcinogenesis model involving initia-
tion with diethylnitrosamine and promotion with phenobarbital,
and the frequency of its expression is increased by the administra-
tion of a progressor agent such as ethylnitrosourea (reviewed by
Pitot et al, 1996). Basic fibroblast growth factor expression is asso-
ciated with squamous carcinogenesis of the head and neck in man,
the expression being detected as early as in carcinomas in situ
(Hughes et al, 1994). Furthermore, constitutive expression of
transforming growth factor a in transgenic mice accelerates
carcinogenic responses to chemical inducers (Tamano et al, 1994)
and also increases the incidence of pancreas and liver cancers in
cooperation with constitutively expressed c-myc (Sandgren et al,
1993). In an in vitro cell culture, MK is undoubtedly an autocrine
growth factor for G401 cells, a Wilms’ tumour cell line expressing
abundant MK, because neutralizing antibodies for MK inhibit
G401 cell growth (Muramatsu et al, 1993). MK also promotes the
proliferation of several cell lines (Muramatsu and Muramatsu,
1991; Nurcombe et al, 1992). Accumulating evidence, including
the present report, supports the autocrine hypothesis for tumour
development, especially in terms of the mechanism by which
oncogenic-activated cells achieve autonomous growth in early
carcinogenesis.
With regard to the regulation of MK gene expression, we
recently found that the MK gene is a target of WT1, a Wilms’
tumour-suppressor gene product, and its expression is down-
regulated by WT1 (Adachi et al, 1996). This may be relevant to the
frequent overexpression of MK in Wilms’ tumours (Tsutsui et al,
1993). As the overexpression of MK is observed not only in
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Figure 4 MK in colorectal tissues, as analysed by Western blotting. Case 24, tubular villous adenoma with severe-grade dysplasia; case 43, colorectal
carcinoma at stage A; case 38, stage B; and case 49, stage C. For case 53, both adenoma, with moderate-grade dysplasia, carcinoma, at stage B and
corresponding normal tissues were available. The level of MK protein expression was much higher in adenomas and carcinomas than in normal tissues.
Table 2 MK expression in colorectal tissues from the same individuals
Case Histopathology Normal tissue Adenoma Carcinoma
47 Carcinoma in stage A and
adenoma with severe-grade dysplasia 2a (–)b 3.2 (+) 3.3 (+)
53 Carcinoma in stage C and
adenoma with moderate-grade dysplasia 2.8 (–) 4.1 (+) 5.1 (+)
54 Carcinoma in stage C and
adenoma with moderate-grade dysplasia 2.3 (–) 2.9 (+) 5.9 (+)
aThe ratio of MK to b-actin in each sample was calculated as described in Figure 2. bThe results of
immunostaining are shown in parentheses: (–), negative; (+), positive.Wilms’ tumours but also in many other human carcinomas, it is
likely that other oncogene or suppressor gene products may modu-
late MK expression.
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